- Home
- IMMX vs STTK Comparison
IMMX vs STTK Comparison
Compare IMMX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- STTK
- Stock Information
- Founded
- IMMX 2014
- STTK 2016
- Country
- IMMX United States
- STTK United States
- Employees
- IMMX N/A
- STTK N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- STTK Health Care
- Exchange
- IMMX Nasdaq
- STTK Nasdaq
- Market Cap
- IMMX 61.1M
- STTK 54.4M
- IPO Year
- IMMX 2021
- STTK 2020
- Fundamental
- Price
- IMMX $2.10
- STTK $1.11
- Analyst Decision
- IMMX Strong Buy
- STTK Hold
- Analyst Count
- IMMX 1
- STTK 3
- Target Price
- IMMX $7.00
- STTK $2.00
- AVG Volume (30 Days)
- IMMX 247.3K
- STTK 314.9K
- Earning Date
- IMMX 11-12-2024
- STTK 11-14-2024
- Dividend Yield
- IMMX N/A
- STTK N/A
- EPS Growth
- IMMX N/A
- STTK N/A
- EPS
- IMMX N/A
- STTK N/A
- Revenue
- IMMX N/A
- STTK $6,435,000.00
- Revenue This Year
- IMMX N/A
- STTK $313.04
- Revenue Next Year
- IMMX $200.00
- STTK N/A
- P/E Ratio
- IMMX N/A
- STTK N/A
- Revenue Growth
- IMMX N/A
- STTK 382.75
- 52 Week Low
- IMMX $1.26
- STTK $0.94
- 52 Week High
- IMMX $7.10
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- IMMX 50.86
- STTK 44.51
- Support Level
- IMMX $2.04
- STTK $1.06
- Resistance Level
- IMMX $2.44
- STTK $1.18
- Average True Range (ATR)
- IMMX 0.31
- STTK 0.11
- MACD
- IMMX -0.03
- STTK 0.00
- Stochastic Oscillator
- IMMX 26.51
- STTK 25.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.